TABLE 1.
Baseline demographic and clinical data of the sample (n = 270).
| Characteristics | N (%) |
|---|---|
| Agea | 58.96 ± 18.43 (SD) |
| Gender | |
| Males | 111 (41.1) |
| Females | 159 (58.9) |
| Co-morbidities | |
| Diabetes | 115 (42.6) |
| Hypertension | 133 (49.3) |
| Hyperlipidemia | 56 (20.7) |
| Ischemic Heart disease | 20 (7.4) |
| Chronic Kidney disease | 29 (6.1) |
| Heart Failure | 23 (8.5) |
| Indications for Anticoagulation | |
| DVT | 55 (20.4) |
| PE | 39 (14.4) |
| AF | 124 (45.9) |
| Stroke | 11 (4) |
| Others | 41 (15.3) |
| Intended duration of anticoagulation | |
| 3 mo | 3 (1.1) |
| 6 mo | 10 (3.7) |
| 12 mo | 2 (0.7) |
| Lifelong | 255 (94.5) |
| Duration of therapy upon recruitment | |
| 0–6 wk | 10 (3.7) |
| More than 6 wk | 260 (96.3) |
| Weekly warfarin dosea | 31.56 ± 17.75 |
| INR test performed | 264 (97.8) |
| Laboratory for INR testing | |
| At KAMC | 205 (75.9) |
| Outside KAMC | 65 (24.1) |
| Target INR | |
| 2.0–3.0 | 247 (91.5) |
| 2.5–3.5 | 6 (2.2) |
| Others | 17 (6.3) |
DVT, deep vein thrombosis; PE, pulmonary embolism; AF, atrial fibrillation.
a
Data are given in mean ± standard deviation.